Contact Us
Drug Search Results
More Filters [+]

KTX-545

Alternative Names: ktx-545, ktx 545, ktx545
Latest Update: 2021-04-10
Latest Update Note: News Article

Product Description

KTX-545 is a IRAK4 degrader for degradation of proteins in tumor cells. (Sourced from: https://investors.kymeratx.com/static-files/015e8e33-3bb6-4d3c-9c05-5863c7df0c56)

Mechanisms of Action: IRAK4 Degrader

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kymera Therapeutics
Company Location: WATERTOWN MA 02472
Company CEO: Nello Mainolfi
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KTX-545

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma, B-Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

04/10/2021

News Article

 Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions